Prostate cancer perspective: Africa versus the world
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i4.1950Keywords:
Prostate Specific Antigen (PSA), Africa, South Africa, Clinical Presentation, TNM-Staging, Digital Rectal Examination, ScreeningAbstract
Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men, with a rising global incidence. Currently, the PCa landscape is vastly different between developed countries and Africa. Of note, owing to various biological, socioeconomic and institutional factors, black African men often present with more advanced disease and suffer greater mortality. This review will focus on the burden of PCa globally and in Africa, compare the state of the disease in Africa with that in more developed regions of the world, and answer the question why it can sometimes look like a ‘different’ disease compared with developed regions. In addition, we address the racial disparities of PCa.
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249. https:// doi.org/10.3322/caac.21660
Dewar M, Kaestner L, Zikhali Q, Jehle K, Sinha S, Lazarus J. Investigating racial differences in clinical and pathological features of prostate cancer in South African men. S Afr J Surg 2018;56(2):54-58.
Marima R, Mbeje M, Hull R, Demetriou D, Mtshali N, Dlamini Z. Prostate cancer disparities and
management in southern Africa: Insights into practices, norms and values. Cancer Manag Res 2022;14:3567-3579. https://doi.org/10.2147/CMAR.S382903
Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol 2023;84(2):191-206. https://doi.org/10.1016/j.eururo.2023.04.021
Ferlay J, Ervik M, Lam F, et al. South Africa. In: Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2020. https://cansa.org.za/files/2021/02/IARC-
Globocan-SA-2020-Fact-Sheet.pdf (accessed 7 November 2023).
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-E386. https://doi.
org/10.1002/ijc.29210
National Health Laboratory Service. National Cancer Registry. 2020. https://www.nicd.ac.za/wp-
content/uploads/2023/04/The-National-Pathology-Cancer-Incidence-Report-2020.pdf (accessed 10
October 2023).
Ramaliba TM, Sithole N, Ncinitwa A, Somdyala NIM. Prostate cancer patterns and trends in the
Eastern Cape Province of South Africa; 1998-2017. Front Public Health 2022;10:882586. https://doi.
org/10.3389/fpubh.2022.882586
Singh E, Underwood JM, Nattey C, Babb C, Sengayi M, Kellett P. South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates. S Afr Med J 2015;105(2):107-109. https://doi.org/10.7196/SAMJ.8858
Heyns CF. Is prostate cancer more common and more aggressive in African men? Afr J Urol 2008;14(2):66-74. https://doi.org/10.1007/s12301-008-0007-y
Tindall EA, Monare LR, Petersen DC, et al. Clinical presentation of prostate cancer in black South Africans. Prostate 2014;74(8):880-891. https://doi.org/10.1002/pros.22806
Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int 2011;108(6):806-813.
https://doi.org/10.1111/j.1464-410X.2011.10365.x
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100(12):888-897. https://doi.org/10.1093/jnci/djn175
Fourcade RO, Benedict Ã, Black LK, Stokes ME, Alcaraz A, Castro R. Treatment costs of prostate cancer in the first year after diagnosis: A short-term cost of illness study for France, Germany, Italy,
Spain and the UK. BJU Int 2010;105(1):49-56. https://doi.org/10.1111/j.1464-410X.2009.08716.x
Trogdon JG, Falchook AD, Basak R, Carpenter WR, Chen RC. Total Medicare costs associated with diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol 2019;5(1):60-66. https://doi.
org/10.1001/jamaoncol.2018.3701
Zaorsky NG, Lin J, Ba D, et al. The cost of prostate cancer care to society and to patients in the United States. J Clin Oncol 2019;37(7_suppl):116. https://doi.org/10.1200/jco.2019.37.7_suppl.116
Makau-Barasa LK, Manirakiza A, Carvalho AL, Rebbeck TR. Prostate cancer screening, diagnostic, treatment procedures and costs in sub-Saharan Africa: A situational analysis. Cancer Control 2022;29:10732748221084932. https://doi.org/10.1177/10732748221084932
Ngcamphalala C, Östensson E, Ginindza TG. The economic burden of prostate cancer in Eswatini. BMC Health Serv Res 2022;22(1):483. https://doi.org/10.1186/s12913-022-07817-6
Discovery Health. Discovery Health Medical Scheme oncology claims tracker: January 2018-December 2018. February 2020. https://www.fanews.co.za/assets/marilyn_2020/ discoveryhealthmedicalschemeoncologyclaimstracker2020.pdf (accessed 1 August 2023).
Gabela NC, Bhadree S, Mathibe LJ. Costs of managing castrate-resistant metastatic prostate cancer patients at Inkosi Albert Luthuli Central Hospital. S Afr J Surg 2021;59(4):176-178.
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – 2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243-262. https://doi.org/10.1016/j.eururo.2020.09.042
Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: Prostate cancer screening. J Urol 2023;210(1):46-53. https://doi.org/10.1097/JU.0000000000003491
Naji L, Randhawa H, Sohani Z, et al. Digital rectal examination for prostate cancer screening in
primary care: A systematic review and meta-analysis. Ann Fam Med 2018;16(2):149-154. https://doi.
org/10.1370/afm.2205
Mottet N, Cornford P, van den Bergh R, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – limited update March 2023. European Association of Urology, 2023. https://uroweb. org/guideline/prostate-cancer/ (accessed 13 January 2024).
Heyns CF, Mathee S, Isaacs A, Kharwa A, de Beer PM, Pretorius MA. Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa. BJU Int 2003;91(9):785-788. https://doi.org/10.1046/j.1464-410X.2003.04241.x
Ajape A, Babata A, Abiola O. Knowledge of prostate cancer screening among native African urban population in Nigeria. Nig Q J Hosp Med 2010;20(2):94-96. https://doi.org/10.4314/nqjhm.v20i2.58044
Mofolo N, Betshu O, Kenna O, et al. Knowledge of prostate cancer among males attending a urology
clinic, a South African study. Springerplus 2015;4(1):67. https://doi.org/10.1186/s40064-015-0824-y
Prostate Cancer Foundation of South Africa. South African prostate cancer guidelines. 2017. https:// prostate-ca.co.za/information-on-the-diagnosis-treatment-of-prostate-cancer/ (accessed 30 November
.
Rebbeck TR, Zeigler-Johnson CM, Heyns CF, Gueye SM. Prostate cancer screening, detection and
treatment practices, among Sub-Saharan African urologists. Afr J Urol 2011;17:85-91. https://doi.
org/10.1007/s12301-011-0016-0
Jones R, Cornford P. EAU and NICE guidelines for the diagnosis and management of prostate cancer. How wide is the channel? J Clin Urol 2018;11(2):149-153. https://doi.org/10.1177/2051415817720353
Streicher J, Meyerson BL, Karivedu V, Sidana A. A review of optimal prostate biopsy: Indications and
techniques. Ther Adv Urol 2019;11:175628721987007. https://doi.org/10.1177/1756287219870074
Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study. Lancet Oncol 2019;20(1):100-109. https://doi.org/10.1016/S1470-2045(18)30569-2
Van der Leest M, Cornel E, Israël B, et al. Head-to-head comparison of transrectal ultrasound- guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A large prospective multicenter clinical study. Eur Urol 2019;75(4):570-578. https://doi.org/10.1016/j.eururo.2018.11.023
Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378(19):1767-1777. https://doi.org/10.1056/NEJMoa1801993
Mohammed TO, Ajape AA, Kuranga SA, Olanipekun HB, Ogunfowora TT. Prostate biopsy: A survey of practice among Nigerian urologists. Afr J Urology 2021;27:135. https://doi.org/10.1186/s12301-021- 00240-z
Udeh EI, Onwujekwe OE, Adewole DA, Onoka CA. Exploring the threshold premium for viable community based health insurance schemes in Nigeria. BMC Res Notes 2016;9:383. https://doi. org/10.1186/s13104-016-2185-1
Jehle KS, Lazarus JM, Barnes RD. A review of transrectal ultrasound guided prostate biopsies: Is there still a role for finger guided prostate biopsies? Afr J Urol 2015;21(1). https://doi.org/10.1016/j. afju.2014.12.002
Heyns CF, Basson J, van der Merwe A, Zarrabi AD. Clinical (non-histological) diagnosis of advanced prostate cancer: Evaluation of treatment outcome after androgen deprivation therapy. S Afr J Surg 2014;52(3):82-85.
Heyns CF, Naudé AM, Ahmed G, Stopforth HB, Stellmacher GA, Visser AJ. Serum prostate-specific antigen as surrogate for the histological diagnosis of prostate cancer. S Afr Med J 2001;91(8):685-689. 40. Jang JY, Kim YS. Is prostate biopsy essential to diagnose prostate cancer in the older patient with
extremely high prostate-specific antigen? Korean J Urol 2012;53(2):82-86. https://doi.org/10.4111/
kju.2012.53.2.82
Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part II: Considerations for a prostate biopsy. J Urol 2023;210(1):54-63. https://doi.org/10.1097/ JU.0000000000003492
Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr 2012;2012(45):152- 156. https://doi.org/10.1093/jncimonographs/lgs035
Li J, Siegel DA, King JB. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014. Ann Epidemiol 2018;28(5):328-330. https://doi.org/10.1016/j. annepidem.2018.03.001
Heyns CF, Fisher M, Lecuona A, van der Merwe A. Prostate cancer among different racial groups in the Western Cape: Presenting features and management. S Afr Med J 2011;101(4):267-270. https://doi. org/10.7196/SAMJ.4420
Le Roux HA, Urry RJ, Sartorius B, Aldous C. Prostate cancer at a regional hospital in South Africa: We are only seeing the tip of the iceberg. S Afr J Surg 2015;53(3-4):57-62.
Lowder D, Rizwan K, McColl C, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett 2022;531:71-82. https://doi.org/10.1016/j. canlet.2022.01.028
Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010;183(5):1792-1797. https://doi. org/10.1016/j.juro.2010.01.015
Riviere P, Luterstein E, Kumar A, et al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 2020;126(8):1683-1690. https://doi. org/10.1002/cncr.32666
McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol 2016;13(2):99- 107. https://doi.org/10.1038/nrurol.2015.298
Ames BN, Grant WB, Willett WC. Does the high prevalence of vitamin D deficiency in African Americans contribute to health disparities? Nutrients 2021;13(2):499. https://doi.org/10.3390/nu13020499
Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 2008;14(12):3823-3831. https://doi.org/10.1158/1078-0432.CCR-07-4566
Petrovics G, Price DK, Lou H, et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis 2019;22(3):406-410. https://doi.org/10.1038/s41391-018-0114-1
Beebe-Dimmer JL, Zuhlke KA, Johnson AM, Liesman D, Cooney KA. Rare germline mutations in African American men diagnosed with early-onset prostate cancer. Prostate 2018;78(5):321-326. https:// doi.org/10.1002/pros.23464
AcheampongE,AduEA,ObirikorangC,etal.AssociationofgeneticvariantswithprostatecancerinAfrica: A concise review. Egypt J Med Human Genet 2021;22:33. https://doi.org/10.1186/s43042-021-00157-w 55. Petersen DC, Jaratlerdsiri W, van Wyk A, et al. African KhoeSan ancestry linked to high-risk prostate
cancer. BMC Med Genomics 2019;12(1):82. https://doi.org/10.1186/s12920-019-0537-0
Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, et al. Cancer in Africa: The untold story. Front Oncol
;11:650117. https://doi.org/10.3389/fonc.2021.650117
Hayes VM, Bornman MSR. Prostate cancer in Southern Africa: Does Africa hold untapped potential
to add value to the current understanding of a common disease? J Glob Oncol 2018;4:1-7. https://doi. org/10.1200/JGO.2016.008862
Downloads
Published
Issue
Section
License
Copyright (c) 2024 B Marais, G Klopper, J John
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
